Psychotropic practice patterns for youth: A 10-year perspective

Julie Magno Zito, Daniel J. Safer, Susan DosReis, James F. Gardner, Laurence Magder, Karen Soeken, Myde Boles, Frances Lynch, Mark A Riddle

Research output: Contribution to journalArticle

Abstract

Objective: To examine changes in the full spectrum of psychotropic medication treatment for youths from 1987 to 1996. Methods: A population-based analysis of community treatment data on nearly 900000 youths enrolled in 2 US health care systems included (1) computerized Medicaid data from 2 states (a midwestern state and a mid-Atlantic state) composed of outpatient prescription claims and enrollment records and (2) computerized prescription dispensing records from a group-model health maintenance organization. Ten 1-year cross-sectional data sets from 1987 through 1996 were analyzed. Results: Total psychotropic medication prevalence for youths increased 2- to 3-fold and included most classes of medication. The rapid growth since 1991 of α-agonists, neuroleptics, and "mood stabilizer" anticonvulsants was particularly notable. The 1996 prevalence of any psychotropic medication among youths younger than 20 years was remarkably similar (5.9%-6.3%) across all 3 sites, with stimulants and antidepressants consistently ranked first and second. Medicaid rates almost always exceeded health maintenance organization rates by large margins, particularly for α-agonists, neuroleptics, "mood stabilizer" anticonvulsants, and lithium. Youths in health maintenance organizations had rates similar to Medicaid-insured youths for antidepressants and hypnotics. Over the decade, there was a proportional increase in females receiving stimulants and in males receiving antidepressants, particularly for the 10- to 14-year-old group. The prevalence ratios of whites to African Americans narrowed substantially in 1 Medicaid site. Conclusions: Youth psychotropic treatment utilization during the 1990s nearly reached adult utilization rates. Youth findings can be used to accurately assess the duration of treatment and unforeseen practice pattern changes, and to identify safety concerns.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalArchives of Pediatrics and Adolescent Medicine
Volume157
Issue number1
StatePublished - Jan 1 2003

Fingerprint

antineoplaston A10
Medicaid
Health Maintenance Organizations
Antidepressive Agents
Anticonvulsants
Antipsychotic Agents
Prescriptions
Therapeutics
Hypnotics and Sedatives
Lithium
African Americans
Outpatients
Delivery of Health Care
Safety
Growth
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Psychotropic practice patterns for youth : A 10-year perspective. / Zito, Julie Magno; Safer, Daniel J.; DosReis, Susan; Gardner, James F.; Magder, Laurence; Soeken, Karen; Boles, Myde; Lynch, Frances; Riddle, Mark A.

In: Archives of Pediatrics and Adolescent Medicine, Vol. 157, No. 1, 01.01.2003, p. 17-25.

Research output: Contribution to journalArticle

Zito, JM, Safer, DJ, DosReis, S, Gardner, JF, Magder, L, Soeken, K, Boles, M, Lynch, F & Riddle, MA 2003, 'Psychotropic practice patterns for youth: A 10-year perspective', Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 1, pp. 17-25.
Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K et al. Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatrics and Adolescent Medicine. 2003 Jan 1;157(1):17-25.
Zito, Julie Magno ; Safer, Daniel J. ; DosReis, Susan ; Gardner, James F. ; Magder, Laurence ; Soeken, Karen ; Boles, Myde ; Lynch, Frances ; Riddle, Mark A. / Psychotropic practice patterns for youth : A 10-year perspective. In: Archives of Pediatrics and Adolescent Medicine. 2003 ; Vol. 157, No. 1. pp. 17-25.
@article{09fa82488c3548c3877544c356db0342,
title = "Psychotropic practice patterns for youth: A 10-year perspective",
abstract = "Objective: To examine changes in the full spectrum of psychotropic medication treatment for youths from 1987 to 1996. Methods: A population-based analysis of community treatment data on nearly 900000 youths enrolled in 2 US health care systems included (1) computerized Medicaid data from 2 states (a midwestern state and a mid-Atlantic state) composed of outpatient prescription claims and enrollment records and (2) computerized prescription dispensing records from a group-model health maintenance organization. Ten 1-year cross-sectional data sets from 1987 through 1996 were analyzed. Results: Total psychotropic medication prevalence for youths increased 2- to 3-fold and included most classes of medication. The rapid growth since 1991 of α-agonists, neuroleptics, and {"}mood stabilizer{"} anticonvulsants was particularly notable. The 1996 prevalence of any psychotropic medication among youths younger than 20 years was remarkably similar (5.9{\%}-6.3{\%}) across all 3 sites, with stimulants and antidepressants consistently ranked first and second. Medicaid rates almost always exceeded health maintenance organization rates by large margins, particularly for α-agonists, neuroleptics, {"}mood stabilizer{"} anticonvulsants, and lithium. Youths in health maintenance organizations had rates similar to Medicaid-insured youths for antidepressants and hypnotics. Over the decade, there was a proportional increase in females receiving stimulants and in males receiving antidepressants, particularly for the 10- to 14-year-old group. The prevalence ratios of whites to African Americans narrowed substantially in 1 Medicaid site. Conclusions: Youth psychotropic treatment utilization during the 1990s nearly reached adult utilization rates. Youth findings can be used to accurately assess the duration of treatment and unforeseen practice pattern changes, and to identify safety concerns.",
author = "Zito, {Julie Magno} and Safer, {Daniel J.} and Susan DosReis and Gardner, {James F.} and Laurence Magder and Karen Soeken and Myde Boles and Frances Lynch and Riddle, {Mark A}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "157",
pages = "17--25",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Psychotropic practice patterns for youth

T2 - A 10-year perspective

AU - Zito, Julie Magno

AU - Safer, Daniel J.

AU - DosReis, Susan

AU - Gardner, James F.

AU - Magder, Laurence

AU - Soeken, Karen

AU - Boles, Myde

AU - Lynch, Frances

AU - Riddle, Mark A

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objective: To examine changes in the full spectrum of psychotropic medication treatment for youths from 1987 to 1996. Methods: A population-based analysis of community treatment data on nearly 900000 youths enrolled in 2 US health care systems included (1) computerized Medicaid data from 2 states (a midwestern state and a mid-Atlantic state) composed of outpatient prescription claims and enrollment records and (2) computerized prescription dispensing records from a group-model health maintenance organization. Ten 1-year cross-sectional data sets from 1987 through 1996 were analyzed. Results: Total psychotropic medication prevalence for youths increased 2- to 3-fold and included most classes of medication. The rapid growth since 1991 of α-agonists, neuroleptics, and "mood stabilizer" anticonvulsants was particularly notable. The 1996 prevalence of any psychotropic medication among youths younger than 20 years was remarkably similar (5.9%-6.3%) across all 3 sites, with stimulants and antidepressants consistently ranked first and second. Medicaid rates almost always exceeded health maintenance organization rates by large margins, particularly for α-agonists, neuroleptics, "mood stabilizer" anticonvulsants, and lithium. Youths in health maintenance organizations had rates similar to Medicaid-insured youths for antidepressants and hypnotics. Over the decade, there was a proportional increase in females receiving stimulants and in males receiving antidepressants, particularly for the 10- to 14-year-old group. The prevalence ratios of whites to African Americans narrowed substantially in 1 Medicaid site. Conclusions: Youth psychotropic treatment utilization during the 1990s nearly reached adult utilization rates. Youth findings can be used to accurately assess the duration of treatment and unforeseen practice pattern changes, and to identify safety concerns.

AB - Objective: To examine changes in the full spectrum of psychotropic medication treatment for youths from 1987 to 1996. Methods: A population-based analysis of community treatment data on nearly 900000 youths enrolled in 2 US health care systems included (1) computerized Medicaid data from 2 states (a midwestern state and a mid-Atlantic state) composed of outpatient prescription claims and enrollment records and (2) computerized prescription dispensing records from a group-model health maintenance organization. Ten 1-year cross-sectional data sets from 1987 through 1996 were analyzed. Results: Total psychotropic medication prevalence for youths increased 2- to 3-fold and included most classes of medication. The rapid growth since 1991 of α-agonists, neuroleptics, and "mood stabilizer" anticonvulsants was particularly notable. The 1996 prevalence of any psychotropic medication among youths younger than 20 years was remarkably similar (5.9%-6.3%) across all 3 sites, with stimulants and antidepressants consistently ranked first and second. Medicaid rates almost always exceeded health maintenance organization rates by large margins, particularly for α-agonists, neuroleptics, "mood stabilizer" anticonvulsants, and lithium. Youths in health maintenance organizations had rates similar to Medicaid-insured youths for antidepressants and hypnotics. Over the decade, there was a proportional increase in females receiving stimulants and in males receiving antidepressants, particularly for the 10- to 14-year-old group. The prevalence ratios of whites to African Americans narrowed substantially in 1 Medicaid site. Conclusions: Youth psychotropic treatment utilization during the 1990s nearly reached adult utilization rates. Youth findings can be used to accurately assess the duration of treatment and unforeseen practice pattern changes, and to identify safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=0037233358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037233358&partnerID=8YFLogxK

M3 - Article

C2 - 12517190

AN - SCOPUS:0037233358

VL - 157

SP - 17

EP - 25

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 1

ER -